These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35781739)

  • 1. Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology.
    Choucair K; Naqash AR; Nebhan CA; Nipp R; Johnson DB; Saeed A
    Oncologist; 2022 Sep; 27(9):778-789. PubMed ID: 35781739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Geriatric Oncology.
    Cook SL; Al Amin M; Bari S; Poonnen PJ; Khasraw M; Johnson MO
    Curr Oncol Rep; 2024 May; 26(5):562-572. PubMed ID: 38587598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper.
    Guven DC; Martinez-Cannon BA; Testa GD; Martins JC; Velasco RN; Kalsi T; Gomes F
    J Geriatr Oncol; 2024 May; 15(4):101742. PubMed ID: 38472009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors.
    Welaya K; Loh KP; Messing S; Szuba E; Magnuson A; Mohile SG; Maggiore RJ
    J Geriatr Oncol; 2020 Apr; 11(3):523-528. PubMed ID: 31175042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
    Nebhan CA; Cortellini A; Ma W; Ganta T; Song H; Ye F; Irlmeier R; Debnath N; Saeed A; Radford M; Alahmadi A; Diamond A; Hoimes C; Ramaiya N; Presley CJ; Owen DH; Abou Alaiwi S; Nassar A; Ricciuti B; Lamberti G; Bersanelli M; Casartelli C; Buti S; Marchetti P; Giusti R; Filetti M; Vanella V; Mallardo D; Macherla S; Sussman TA; Botticelli A; Galetta D; Catino A; Pizzutilo P; Genova C; Dal Bello MG; Kalofonou F; Daniels E; Ascierto PA; Pinato DJ; Choueiri TK; Johnson DB; Marron TU; Wang Y; Naqash AR
    JAMA Oncol; 2021 Dec; 7(12):1856-1861. PubMed ID: 34734989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic review.
    Özkan A; van den Bos F; Mooijaart SP; Slingerland M; Kapiteijn E; de Miranda NFCC; Portielje JEA; de Glas NA
    Crit Rev Oncol Hematol; 2024 Feb; 194():104259. PubMed ID: 38199430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy.
    Wong SK; Nebhan CA; Johnson DB
    Front Immunol; 2021; 12():786046. PubMed ID: 34868071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy comes of age: Immune aging & checkpoint inhibitors.
    Elias R; Karantanos T; Sira E; Hartshorn KL
    J Geriatr Oncol; 2017 May; 8(3):229-235. PubMed ID: 28223073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
    Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
    J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
    Wong SK; Blum SM; Sun X; Da Silva IP; Zubiri L; Ye F; Bai K; Zhang K; Ugurel S; Zimmer L; Livingstone E; Schadendorf D; Serra-Bellver P; Muñoz-Couselo E; Ortiz C; Lostes J; Huertas RM; Arance A; Pickering L; Long GV; Carlino MS; Buchbinder EI; Vázquez-Cortés L; Jara-Casas D; Márquez-Rodas I; González-Espinoza IR; Balko JM; Menzies AM; Sullivan RJ; Johnson DB
    Eur J Cancer; 2023 Mar; 181():188-197. PubMed ID: 36680880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors for the treatment of melanoma.
    Sabbatino F; Liguori L; Pepe S; Ferrone S
    Expert Opin Biol Ther; 2022 May; 22(5):563-576. PubMed ID: 35130816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aging, immune senescence, and immunotherapy: A comprehensive review.
    Elias R; Hartshorn K; Rahma O; Lin N; Snyder-Cappione JE
    Semin Oncol; 2018 Aug; 45(4):187-200. PubMed ID: 30539714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
    Michielin O; Lalani AK; Robert C; Sharma P; Peters S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Durbin SM; Zubiri L; Niemierko A; Bardia A; Sullivan RJ; McEwen C; Mulvey TM; Allen IM; Lawrence DP; Cohen JV; Hochberg EP; Ryan DP; Petrillo LA; Reynolds KL
    Oncologist; 2021 Jan; 26(1):49-55. PubMed ID: 33044765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.